European Patent Office

T 1938/09 (TRANSDERMAL DELIVERY OF BUPRENORPHINE / EURO-CELTIQUE) vom 09.03.2015

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2015:T193809.20150309
Datum der Entscheidung
9. März 2015
Aktenzeichen
T 1938/09
Antrag auf Überprüfung von
-
Anmeldenummer
98906678.2
Verfahrenssprache
Englisch
Verteilung
An die Kammervorsitzenden verteilt (C)
Amtsblattfassungen
Keine AB-Links gefunden
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
SUSTAINED ANALGESIA ACHIEVED WITH TRANSDERMAL DELIVERY OF BUPRENORPHINE
Name des Antragstellers
EURO-CELTIQUE S.A.
Name des Einsprechenden
Hexal AG
Acino AG
Kammer
3.3.02
Leitsatz
-
Relevante Rechtsnormen
Basic proposal for the revision of the EPC MR/2/00European Patent Convention Art 112a(2)(c)European Patent Convention Art 112a(3)European Patent Convention Art 114(2)European Patent Convention Art 116(4)European Patent Convention Art 123(2)European Patent Convention Art 24European Patent Convention Art 54(2)Rules of procedure of the Boards of Appeal Art 13Rules of procedure of the Boards of Appeal Art 15(2)Rules of procedure of the Boards of Appeal Art 3(2)
Schlagwörter
Admissibility of objection of partiality (yes) - No delay and sufficient substantiation
Admissibility of auxiliary requests (yes) - Bona fide attemps to remedy newly raised deficiencies
Admissibility of auxiliary requests (no) - Not clearly allowable and raising complex problems at late stage
Postponement of oral proceedings because of pending petition for review of a decision rejecting an objection based on suspected partiality (no) - No suspensive effect
Referral of questions to the Enlarged Board of Appeal (no)
Amendments - extension beyond the content of the application as filed (yes)
Claims - clarity after amendment (no)
Orientierungssatz
-
Zitierende Akten
R 0016/22

Order

For these reasons it is decided that:

The appeal is dismissed.